Tony Berberabe's profile photo

Tony Berberabe

Cranbury

Assistant Managing Editor at Targeted Oncology

Assistant Managing Editor, Targeted Therapies in Oncology. Tweets are my own.

Featured in: Favicon targetedonc.com Favicon newsbreak.com Favicon cancernetwork.com Favicon onclive.com Favicon curetoday.com Favicon urologytimes.com Favicon oncnursingnews.com Favicon cgtlive.com Favicon ourcommunitynow.com Favicon ajmc.com

Articles

  • Linvoseltamab/Bortezomib Shows Consistent Safety in Relapsed/Refractory Multiple Myeloma

    2 weeks ago | targetedonc.com | Tony Berberabe

    The combination of linvoseltamab, a BCMA x CD3 bispecific human monoclonal antibody, and bortezomib (Velcade) demonstrated a manageable safety profile in patients with relapsed/refractory multiple myeloma (RRMM), according to initial findings from the phase 1 LINKER-MM2 trial (NCT05137054).

  • Expanded Approaches Focus on Balancing Efficacy and Toxicity in NSCLC

    2 weeks ago | targetedonc.com | Tony Berberabe

    Expanded approaches in non–small lung cancer (NSCLC) highlight much of the data presented during the European Lung Cancer Congress (ELCC 2025), which took place in Paris, France, from March 26 to 29, 2025. Although using osimertinib (Tagrisso) remains a frontline stalwart, data presented during ELCC 2025 can spur additional conversations with clinicians and their patients regarding optional approaches that balance efficacy with toxicity.

  • Durable PFS and OS Rates Maintained for Fixed-Dose Ibrutinib/Venetoclax in CLL/SLL

    2 weeks ago | targetedonc.com | Tony Berberabe

    The final analysis of the CAPTIVATE trial (NCT02910583) revealed that fixed dose ibrutinib (Imbruvica) plus venetoclax (Venclax) continued to have durable progression-free survival (PFS) rates and overall survival (OS) rates with long-term follow-up in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including patients with high-risk genomic features.

  • Fully Remote Telehealth Cancer Clinical Trial Aims to Expand Treatment Access Nationwide

    2 weeks ago | targetedonc.com | Tony Berberabe

    A fully remote phase 2 telehealth trial (NCT06906562)1 that delivers oral pancreatic treatment directly to patients’ homes while coordinating care with local oncologists was launched recently at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and the Richard J. Solove Research Institute (OSUCCC-James). The trial, which opened May 8, 2025, seeks to enroll patients with FGFR-mutated pancreatic cancer.

  • Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

    3 weeks ago | cancernetwork.com | Tony Berberabe

    Results from the COMRADE trial (NCT03317392) shared at the 2025 American Society of Clinical Oncology Annual Meeting showed olaparib (Lynparza) in combination with radium-223 (Xofigo) demonstrated superior radiographic progression-free survival (rPFS) vs radium-223 alone in patients with castration-resistant prostate cancer (CRPC), regardless of hormone recombination repair (HRR) status.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
319
Tweets
486
DMs Open
No
Tony Berberabe
Tony Berberabe @OncBiz_Wiz
20 May 24

RT @TargetedOnc: Check out our coverage on a phase 1/2 trial (NCT04474470) evaluating NT219 in combination with cetuximab (Erbitux) in squa…

Tony Berberabe
Tony Berberabe @OncBiz_Wiz
15 May 24

Telehealth Framework Sets Stage for Decentralized Clinical Trials in Oncology https://t.co/G5Gd8AyOHc via @targetedonc

Tony Berberabe
Tony Berberabe @OncBiz_Wiz
11 Sep 23

@ilca2023 - Are there any press releases that came out of ILCA 2023 and are they available?